Article Carousel
Toshiba Open Sessions 2022: The Future of the Quantum Economy
The full video interview featuring Andrew Lord, Senior Manager of Optical Research at BT and Dr Andrew Shields, Head of Toshiba’s Quantum Technology Division.
The future of quantum-secure networking
Experts discuss what’s next for QKD technology – including how, and why, to implement an international quantum network.
The BT-Toshiba quantum-secure networking partnership
Experts discuss how BT and Toshiba worked together to bring quantum-secure networking to UK networks and customers.
Latest stories
-
Video
The future of quantum-secure networking
Experts discuss what’s next for QKD technology – including how, and why, to implement an international quantum network.
-
Video
The BT-Toshiba quantum-secure networking partnership
Experts discuss how BT and Toshiba worked together to bring quantum-secure networking to UK networks and customers.
The full video interview featuring Andrew Lord, Senior Manager of Optical Research at BT and Dr Andrew Shields, Head of Toshiba’s Quantum Technology Division.
The future of quantum-secure networking
Experts discuss what’s next for QKD technology – including how, and why, to implement an international quantum network.
The BT-Toshiba quantum-secure networking partnership
Experts discuss how BT and Toshiba worked together to bring quantum-secure networking to UK networks and customers.
Latest posts from LinkedIn
Connect with our team Luma Musa and Sourabh Khandelwal at Booth 1351 during ECOC 2026 to dive deep into our QKD technology.
#QKD #QuantumSecurity #ECOC2026 #OpticalNetworking
https://lnkd.in/eT6dNUgj
💊 A new milestone for computational drug discovery: AOI Biosciences and Toshiba Corporation have been granted a Japanese patent for a jointly developed technology that predicts allosteric sites in proteins using Toshiba’s quantum-inspired optimisation solution, “SQBM+™”.
The technology is designed to support drug discovery for proteins that can be difficult to target through conventional approaches. In validation studies, it identified known allosteric sites with more than 80% accuracy.
The patented technology is expected to streamline the search for promising allosteric sites and enable new drug-discovery approaches for targets previously considered undruggable.
👉Learn more: https://lnkd.in/eZrxD4-D
#DrugDiscovery #DrugTargets #Allosteric #ComputationalBiology #QuantumInspired #Toshiba
To access this document please complete the form below:
Thanks for your interest in Toshiba Quantum Technology.
Would you like to visit our US site?
NO, STAY ON THIS SITE
Thanks for your interest in Toshiba Quantum Technology.
Would you like to visit our Europe site?
NO STAY ON THIS SITE